Home > Publications Database > Alpha-Synuclein Demonstrates Varying Binding Affinities With Different Tau Isoforms. > print

001     277807
005     20250427001131.0
024 7 _ |a 10.1111/jnc.70053
|2 doi
024 7 _ |a pmid:40165586
|2 pmid
024 7 _ |a 0022-3042
|2 ISSN
024 7 _ |a 1471-4159
|2 ISSN
024 7 _ |a altmetric:175792909
|2 altmetric
037 _ _ |a DZNE-2025-00479
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Fischer, Anna-Lisa
|0 P:(DE-2719)9001954
|b 0
|e First author
245 _ _ |a Alpha-Synuclein Demonstrates Varying Binding Affinities With Different Tau Isoforms.
260 _ _ |a Oxford
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1745322758_32642
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The hallmark of various neurodegenerative diseases is the accumulation and aggregation of amyloidogenic proteins, such as amyloid-beta (Aβ) and tau in Alzheimer's disease (AD) and alpha-synuclein (aSyn) in synucleinopathies. Many neurodegenerative diseases express mixed pathology. For instance, Lewy bodies are reported in tauopathies and neurofibrillary tau-tangles are detected in synucleinopathies, suggesting a potential co-existence or crosstalk of misfolded aSyn and tau. In the present study, we investigated the binding characteristics of monomeric aSyn with different tau isoforms by using surface plasmon resonance (SPR) spectroscopy allowing monitoring direct protein-protein interactions and their potential co-localization using SH-SY5Y cells. The calculation of the binding parameters (association and dissociation rate constants) indicated the strongest binding affinity between aSyn and tau isoform 1N3R followed by tau 2N3R and tau 2N4R. Co-localization studies in SH-SY5Y cells, treated with aSyn and all six tau isoforms revealed an intracellular co-localization of aSyn with different isoforms of tau. Subcellular fractionation confirmed the cellular uptake and colocalization of tau and aSyn in the same compartment, showing their expression in membrane, nuclear, and cytoskeletal fractions. Understanding the intricate interplay between aSyn and tau is crucial for unraveling the pathophysiology of PD, AD, and related neurodegenerative disorders, ultimately paving the way for the development of effective treatments targeting this interaction. In conclusion, our data indicate that aSyn and tau are direct interaction partners with varying binding affinities depending on the tau isoform. This interaction may be significant for understanding the pathophysiology of dementia with mixed pathologies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a Parkinson's disease
|2 Other
650 _ 7 |a alpha‐synuclein
|2 Other
650 _ 7 |a interaction
|2 Other
650 _ 7 |a synucleinopathies
|2 Other
650 _ 7 |a tau
|2 Other
650 _ 7 |a tauopathies
|2 Other
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 7 |a Protein Isoforms
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a alpha-Synuclein: metabolism
|2 MeSH
650 _ 2 |a Protein Isoforms: metabolism
|2 MeSH
650 _ 2 |a Protein Binding: physiology
|2 MeSH
650 _ 2 |a Cell Line, Tumor
|2 MeSH
650 _ 2 |a Surface Plasmon Resonance
|2 MeSH
700 1 _ |a Schmitz, Matthias
|0 P:(DE-2719)9000287
|b 1
|u dzne
700 1 _ |a Thom, Tobias
|0 P:(DE-2719)9000851
|b 2
700 1 _ |a Zafar, Saima
|0 P:(DE-2719)9000358
|b 3
|u dzne
700 1 _ |a Younas, Neelam
|0 P:(DE-2719)9001558
|b 4
700 1 _ |a da Silva Correia, Susana
|0 P:(DE-2719)9000766
|b 5
|u dzne
700 1 _ |a Silva-Correia, Susana
|0 P:(DE-2719)9000766
|b 6
|u dzne
700 1 _ |a Canaslan, Sezgi
|0 P:(DE-2719)9001944
|b 7
700 1 _ |a Zerr, Inga
|0 P:(DE-2719)2000058
|b 8
|e Last author
|u dzne
773 _ _ |a 10.1111/jnc.70053
|g Vol. 169, no. 4, p. e70053
|0 PERI:(DE-600)2020528-4
|n 4
|p e70053
|t Journal of neurochemistry
|v 169
|y 2025
|x 0022-3042
856 4 _ |u https://pub.dzne.de/record/277807/files/DZNE-2025-00479_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/277807/files/DZNE-2025-00479_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:277807
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001954
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000287
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000851
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9000358
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9001558
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9000766
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000766
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9001944
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000058
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-01
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-01
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROCHEM : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-01
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-01
920 1 _ |0 I:(DE-2719)1440011-1
|k AG Zerr
|l Translational Studies and Biomarker
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1440011-1
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21